US Acute Agitation Aggression Treatment Market

ID: MRFR/Pharma/15218-HCR

100 Pages

Garvit Vyas

September 2025

US Acute Agitation Aggression Treatment Market Research Report By Drug Class (First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Others), By Route of Administration (Oral, Intramuscular, Others), By Indication (Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-induced Agitation and Aggression, Alcohol Withdrawal, Others) and By End User (Hospitals & Clinics, Psychiatric Care Facilities, Others) - Forecast to 2035

US Acute Agitation Aggression Treatment Market Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Infographic

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

US Acute Agitation Aggression Treatment Market Summary

The United States Acute Agitation Aggression Treatment market is projected to grow significantly from 1.35 USD Billion in 2024 to 2.85 USD Billion by 2035.

Key Market Trends & Highlights

US Acute Agitation Aggression Treatment Key Trends and Highlights

The market is expected to experience a compound annual growth rate (CAGR) of 7.03% from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 2.85 USD Billion, indicating robust growth opportunities.
In 2024, the market is valued at 1.35 USD Billion, reflecting the increasing demand for effective treatment options.
Growing adoption of innovative treatment modalities due to rising awareness of mental health issues is a major market driver.

US Acute Agitation Aggression Treatment Market

CAGR

7.03%

Market Size & Forecast

2024 Market Size	1.35 (USD Billion)
2035 Market Size	2.85 (USD Billion)
CAGR (2025-2035)	7.03%

Major Players

Eli Lilly, Bristol Myers Squibb, Acadia Pharmaceuticals, Neurocrine Biosciences, Horizon Therapeutics, Pfizer, Lannett Company, Opiant Pharmaceuticals, Roche, Sanofi, Johnson and Johnson, GSK, Teva Pharmaceuticals, IntraCellular Therapies

US Acute Agitation Aggression Treatment Market Trends

The US Acute Agitation Aggression Treatment Market is experiencing several notable trends driven by increased awareness of mental health issues and a growing demand for effective treatment options. The opioid crisis and rising instances of mental health disorders, particularly in the wake of the COVID-19 pandemic, have prompted healthcare providers to seek alternative therapeutic approaches.

This focus on mental health has led to a surge in the development and approval of new pharmacological treatments, including antipsychotics and mood stabilizers, tailored specifically for acute agitation and aggressive behavior. Additionally, innovative non-pharmacological interventions such as de-escalation strategies and cognitive-behavioral therapy are gaining traction among healthcare professionals.

Furthermore, the aging population in the US, which is often accompanied by a rise in cognitive impairments and related agitation, presents a unique opportunity for healthcare providers to create specialized treatment plans for this demographic. Recent trends also indicate a shift towards personalized medicine, with advancements in genomics and patient-specific interventions playing a role in improving treatment outcomes.

Healthcare facilities are increasingly adopting telehealth services, allowing for real-time monitoring and management of patients exhibiting acute agitation. This digital trend not only enhances accessibility but also ensures that timely interventions are provided to mitigate aggression effectively. As the landscape continues to evolve, embracing these trends will be crucial for stakeholders aiming to improve patient outcomes in the US Acute Agitation Aggression Treatment Market.

Market Segment Insights

Acute Agitation Aggression Treatment Market Drug Class Insights

The US Acute Agitation Aggression Treatment Market is characterized by its diverse Drug Class segment, which includes various categories crucial for managing acute agitation and aggression. This market segment reflects a growing understanding of the intricacies of mental health, as well as the need for effective treatment options for patients facing acute episodes.

First-Generation Anti-Psychotics historically played a significant role in this market due to their established efficacy in managing severe agitation and psychotic symptoms, while also demonstrating a clear profile of side effects. They often serve as a cornerstone in treatment protocols, particularly in emergency settings, highlighting their importance in providing immediate relief.

On the other hand, Second-Generation Anti-Psychotics have gained prominence in recent years, offering a more favorable side effect profile, which is critical in promoting patient adherence to treatment. These medications often represent a substantial portion of treatment regimens due to innovations in their formulation, making them preferred options among healthcare professionals and patients alike.

Benzodiazepines, known for their rapid onset of action, play an essential role in the acute management of agitation, particularly in emergency departments, where swift intervention is vital. They are often combined with other classes of medications to balance efficacy and tolerability, indicating their flexibility in treatment paradigms.

In addition, other pharmacological options, categorized under 'Others', include various adjunctive therapies that may not fit neatly within the primary drug classes but provide necessary alternatives or complement existing treatments. This can include mood stabilizers and anticonvulsants, both of which have shown utility in specific scenarios of acute agitation.

Acute Agitation Aggression Treatment Market Route of Administration Insights

The Route of Administration segment in the US Acute Agitation Aggression Treatment Market plays a crucial role in defining treatment efficacy and patient compliance. Oral administration is favored for its convenience and ease of use, making it significant in outpatient settings, while Intramuscular routes often ensure quicker onset of action, which is vital for acute management in emergency situations.

Moreover, the preference for Intramuscular administration is attributed to its ability to bypass gastrointestinal limitations and achieve rapid therapeutic levels. The Others category, which encompasses various alternative routes, is becoming increasingly relevant as new formulations and delivery methods are developed, offering tailored solutions for specific patient needs.

As the US healthcare system continues to evolve, understanding the dynamics of these administration routes will be essential for optimizing treatment protocols and improving patient outcomes. The ongoing advancements in pharmaceuticals and biotechnology promise to enhance existing routes and potentially introduce innovative methods that could transform the Acute Agitation Aggression Treatment landscape.

Acute Agitation Aggression Treatment Market Indication Insights

The US Acute Agitation Aggression Treatment Market is significantly influenced by the various indications that necessitate treatment. Schizophrenia represents a considerable portion of this market, as individuals with this disorder often experience acute agitation and aggression that require immediate intervention.

Dementia is another pertinent indication, where behavioral disturbances can arise as the condition progresses, leading to the need for effective treatment options. Bipolar Disorder also contributes meaningfully, as mood swings can escalate into episodes of aggression that require management.

Additionally, Depression can lead to heightened states of agitation, making it a critical area within the market. Drug-induced agitation and aggression, particularly related to substance withdrawal, further amplify the demand for effective treatment options.

Alcohol Withdrawal serves as another major indication in the market, as individuals experiencing withdrawal symptoms may exhibit aggressive behaviors necessitating interventions. Lastly, there are other conditions contributing to the market growth, reflecting the diverse nature of acute agitation and aggression in various patient populations.

The need for effective management strategies across these indications drives innovation and development within the US Acute Agitation Aggression Treatment Market, presenting multiple opportunities for stakeholders to address these critical mental health challenges.

Acute Agitation Aggression Treatment Market End User Insights

The US Acute Agitation Aggression Treatment Market's End User segmentation primarily includes Hospitals and Clinics, Psychiatric Care Facilities, and Others. Hospitals and Clinics are crucial in this market as they serve as the first line of response to individuals experiencing acute agitation and aggression.

These facilities are equipped to provide immediate care and stabilization, significantly contributing to efficient patient outcomes. In contrast, Psychiatric Care Facilities play a vital role by offering specialized treatment environments tailored for managing severe behavioral conditions.

This segment not only helps in de-escalating crises but also focuses on long-term recovery strategies. Other facilities, which may include community health organizations and rehabilitation centers, supplement the overall treatment ecosystem, providing alternative support mechanisms for patients post-crisis.

The collaboration among these various End Users ensures a comprehensive approach to tackling acute agitation and aggression, ultimately promoting patient safety and enhancing therapeutic effectiveness within the US healthcare system. Market growth in this segment is further fueled by increasing awareness of mental health issues and a rise in policy initiatives aimed at improving mental wellness across the country.

As such, understanding these End User dynamics is essential for stakeholders looking to navigate the evolving landscape of acute agitation and aggression treatment.

Get more detailed insights about US Acute Agitation Aggression Treatment Market

Request Free Sample

Key Players and Competitive Insights

The US Acute Agitation Aggression Treatment Market is characterized by a diverse range of players providing medical solutions aimed at managing severe agitation and aggression, often seen in psychiatric and neurological conditions. This market is shaped by increasing awareness of mental health disorders and a growing demand for effective treatment options.

These dynamics are further influenced by stringent regulatory frameworks, ongoing innovation in pharmaceuticals, and a focus on minimizing side effects associated with existing therapies. The competitive landscape is evolving, with established companies leveraging their research and development capabilities to introduce novel products that address unmet needs in patient care.

The market's expansion is further propelled by collaborations and partnerships among industry players, enhancing their ability to provide comprehensive solutions.

Eli Lilly has established a significant presence in the US Acute Agitation Aggression Treatment Market through its portfolio of psychiatric medications. The company's strengths lie in its robust research and development pipeline, which is focused on creating innovative treatments for various mental health conditions, including those exhibiting acute agitation.

Eli Lilly's commitment to clinical trials and evidence-based methodologies has positioned it favorably among healthcare professionals, while its strategic marketing efforts enhance product visibility. The company has also developed strong relationships with key opinion leaders in psychiatry, further solidifying its reputation in this specialized field. Eli Lilly's emphasis on patient-centric approaches and accessibility also contributes to its competitive edge in the US market.

Bristol Myers Squibb has a noteworthy footprint in the US Acute Agitation Aggression Treatment Market, driven by its well-established portfolio of psychiatric drugs and its focus on neurological health. The company has made substantial investments in research aimed at addressing critical symptoms associated with mental health disorders, ensuring that its key products remain highly relevant.

Bristol Myers Squibb's extensive market presence is facilitated by a network of partnerships, mergers, and collaborations that enhance its capacity to innovate and provide comprehensive treatment options. With a focus on expanding its product offerings, Bristol Myers Squibb continues to engage in strategic acquisitions that bolsters its capabilities in the mental health space. The company is recognized for its commitment to maintaining high standards of quality and efficacy, which strengthens its position as a leader in the US Acute Agitation Aggression Treatment Market.

Key Companies in the US Acute Agitation Aggression Treatment Market market include

Industry Developments

The US Acute Agitation Aggression Treatment Market has recently witnessed significant movements, with companies like Eli Lilly, Acadia Pharmaceuticals, and Pfizer continuing to innovate and expand their treatment options for acute agitation and aggression. Notably, Acadia Pharmaceuticals has focused on developing its treatment portfolio specifically targeting neuropsychiatric conditions, contributing to its growth potential in this segment.

In October 2023, Eli Lilly announced a new phase of Clinical Trials for a treatment aimed at acute agitation, signaling its commitment to advancing therapeutic options. Across the industry, mergers and acquisitions have played a role in shaping market dynamics. For example, in June 2022, GSK acquired a biotech company specializing in treatments related to agitation and aggression, enhancing its position in the market.

The valuation of key players like Neurocrine Biosciences and Sanofi has been positively influenced by increasing demand for effective treatments, driven by rising awareness of mental health issues and the opioid crisis. The market growth is further stimulated by regulatory support for rapid drug approval processes and an increasing number of Research and Development initiatives focused on improving patient outcomes. Over the last two years, the market has increasingly aligned its strategies with patient-centered care models.

Market Segmentation

Acute Agitation Aggression Treatment Market End User Outlook

Hospitals & Clinics
Psychiatric Care Facilities
Others

Acute Agitation Aggression Treatment Market Drug Class Outlook

First-Generation Anti-Psychotics
Second-Generation Anti-Psychotics
Benzodiazepines
Others

Acute Agitation Aggression Treatment Market Indication Outlook

Schizophrenia
Dementia
Bipolar Disorder
Depression
Drug-induced Agitation and Aggression
Alcohol Withdrawal
Others

Acute Agitation Aggression Treatment Market Route of Administration Outlook

Oral
Intramuscular
Others

Report Scope

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	1.22(USD Billion)
MARKET SIZE 2024	1.35(USD Billion)
MARKET SIZE 2035	2.85(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.029% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Eli Lilly, BristolMyers Squibb, Acadia Pharmaceuticals, Neurocrine Biosciences, Horizon Therapeutics, Pfizer, Lannett Company, Opiant Pharmaceuticals, Roche, Sanofi, Johnson and Johnson, GSK, Teva Pharmaceuticals, IntraCellular Therapies
SEGMENTS COVERED	Drug Class, Route of Administration, Indication, End User
KEY MARKET OPPORTUNITIES	Innovative drug development, Telehealth treatment solutions, Behavioral health integration, Non-pharmacological interventions, Market expansion for pediatric treatments
KEY MARKET DYNAMICS	increasing patient population, rising awareness and training, regulatory approvals for new therapies, efficacy of combination therapies, growth in telehealth services
COUNTRIES COVERED	US

FAQs

What is the expected market size of the US Acute Agitation Aggression Treatment Market in 2024?

The US Acute Agitation Aggression Treatment Market is expected to be valued at 1.35 USD Billion in 2024.

What market value is projected for the US Acute Agitation Aggression Treatment Market by 2035?

By 2035, the US Acute Agitation Aggression Treatment Market is projected to reach a value of 2.85 USD Billion.

What is the forecasted compound annual growth rate (CAGR) for the US Acute Agitation Aggression Treatment Market from 2025 to 2035?

The forecasted CAGR for the market from 2025 to 2035 is 7.029%.

Which drug class is expected to dominate the US Acute Agitation Aggression Treatment Market?

The Second-Generation Anti-Psychotics drug class is expected to dominate the market.

What is the market size for First-Generation Anti-Psychotics in 2024?

The market size for First-Generation Anti-Psychotics is valued at 0.4 USD Billion in 2024.

How much is the Second-Generation Anti-Psychotics segment expected to be worth by 2035?

The Second-Generation Anti-Psychotics segment is expected to be worth 1.1 USD Billion by 2035.

What market value is anticipated for Benzodiazepines in 2024?

In 2024, the market value for Benzodiazepines is anticipated to be 0.3 USD Billion.

Who are the key players in the US Acute Agitation Aggression Treatment Market?

Key players include Eli Lilly, Bristol-Myers Squibb, Acadia Pharmaceuticals, and Pfizer.

What growth opportunities are present in the US Acute Agitation Aggression Treatment Market?

Emerging trends in personalized medicine and technological advancements present significant growth opportunities.

What is the projected market size for Others drug class by 2035?

The Others drug class is projected to reach a market size of 0.25 USD Billion by 2035.

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027